• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿科生物标志物:被遗忘的儿童生物标志物。

Biomarkers in pediatrics: children as biomarker orphans.

机构信息

Division of Transfusion Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Proteomics Clin Appl. 2010 Dec;4(12):915-21. doi: 10.1002/prca.201000062.

DOI:10.1002/prca.201000062
PMID:21137032
Abstract

Biomarkers have enormous potential to improve patient care by establishing tests of diagnosis, prognosis, and treatment effects. Successfully translating a biomarker from discovery to clinical application demands high-quality discovery research and high-quality clinical studies for biomarker validation; however, there are additional challenges that face biomarker research in pediatrics. There are also additional characteristics of pediatric medicine that make biomarker research especially needed. This review focuses on the fundamentals of biomarkers, the additional considerations needed for applying biomarker research to children, and recommendations for advancing pediatric biomarker research.

摘要

生物标志物具有通过建立诊断、预后和治疗效果的测试来改善患者护理的巨大潜力。成功地将生物标志物从发现转化为临床应用需要高质量的发现研究和高质量的临床研究来验证生物标志物;然而,儿科生物标志物研究还面临其他挑战。儿科医学还有其他特点,使得生物标志物研究尤为必要。这篇综述重点介绍了生物标志物的基本原理,以及将生物标志物研究应用于儿童所需的额外考虑因素,并为推进儿科生物标志物研究提出了建议。

相似文献

1
Biomarkers in pediatrics: children as biomarker orphans.儿科生物标志物:被遗忘的儿童生物标志物。
Proteomics Clin Appl. 2010 Dec;4(12):915-21. doi: 10.1002/prca.201000062.
2
From research to regulated: challenges in transferring methods.从研究到规范:方法转化中的挑战。
Bioanalysis. 2009 May;1(2):285-91. doi: 10.4155/bio.09.51.
3
Urinary proteomics--a tool for biomarker discovery.尿蛋白质组学——生物标志物发现的工具。
Ren Fail. 2010 Jan;32(2):259-68. doi: 10.3109/08860221003599759.
4
Biomarkers for pediatric urological disease.小儿泌尿系统疾病的生物标志物
Curr Opin Urol. 2009 Jul;19(4):397-401. doi: 10.1097/MOU.0b013e32832c90ec.
5
Methodological and analytic considerations for blood biomarkers.血液生物标志物的方法学和分析学考虑因素。
Prog Cardiovasc Dis. 2012 Jul-Aug;55(1):25-33. doi: 10.1016/j.pcad.2012.05.001.
6
Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.支持药物研发或临床诊断/预后的蛋白质生物标志物的方法验证。
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1259-71. doi: 10.1016/j.jchromb.2008.11.022. Epub 2008 Nov 18.
7
[The designs of exploratory biomarker study].[探索性生物标志物研究的设计]
Nihon Rinsho. 2012 May;70(5):874-9.
8
Development and validation of flow cytometry methods for pharmacodynamic clinical biomarkers.药效学生物标志物流式细胞术方法的开发与验证
Bioanalysis. 2010 Sep;2(9):1617-26. doi: 10.4155/bio.10.33.
9
The role of tissue microarrays in prostate cancer biomarker discovery.组织微阵列在前列腺癌生物标志物发现中的作用。
Adv Anat Pathol. 2007 Nov;14(6):408-18. doi: 10.1097/PAP.0b013e318155709a.
10
How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease.生物标志物操作指南:生物标志物的定义、验证和应用,附有心血管疾病的实例。
Postgrad Med J. 2009 Oct;85(1008):538-45. doi: 10.1136/pgmj.2008.073759.

引用本文的文献

1
Delta-S-Cys-Albumin as a Marker of Pediatric Biospecimen Integrity.作为儿科生物样本完整性标志物的δ-S-半胱氨酸白蛋白
Biopreserv Biobank. 2024 Dec;22(6):578-585. doi: 10.1089/bio.2023.0121. Epub 2024 Apr 23.
2
An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.一种综合转录组学方法,用于鉴定儿童肾移植受者中环孢素肾毒性的分子标志物。
Int J Mol Sci. 2021 May 21;22(11):5414. doi: 10.3390/ijms22115414.
3
Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review.
炎症性肠病中的氧化应激标志物:系统评价
Diagnostics (Basel). 2020 Aug 17;10(8):601. doi: 10.3390/diagnostics10080601.
4
Assessment of brain-derived neurotrophic factor and osteopontin in a healthy pediatric population.健康儿童群体中脑源性神经营养因子和骨桥蛋白的评估。
J Circ Biomark. 2018 Oct 18;7:1849454418806136. doi: 10.1177/1849454418806136. eCollection 2018 Jan-Dec.
5
Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children.创新研究设计优化婴儿和儿童临床药理学研究。
J Clin Pharmacol. 2018 Oct;58 Suppl 10(Suppl 10):S58-S72. doi: 10.1002/jcph.1053.
6
Useful pharmacodynamic endpoints in children: selection, measurement, and next steps.儿童中有用的药效终点:选择、测量和下一步。
Pediatr Res. 2018 Jun;83(6):1095-1103. doi: 10.1038/pr.2018.38. Epub 2018 Apr 18.
7
Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives.新生儿及儿童药物疗法的发展:科学与监管要求
Pediatr Clin North Am. 2017 Dec;64(6):1185-1196. doi: 10.1016/j.pcl.2017.08.015.
8
Children as Biomarker Orphans: Progress in the Field of Pediatric Biomarkers.作为生物标志物孤儿的儿童:儿科生物标志物领域的进展。
J Pediatr. 2018 Feb;193:14-20.e31. doi: 10.1016/j.jpeds.2017.08.077. Epub 2017 Oct 12.
9
The proteomics of lung injury in childhood: challenges and opportunities.儿童肺损伤的蛋白质组学:挑战与机遇
Clin Proteomics. 2016 Feb 29;13:5. doi: 10.1186/s12014-016-9106-0. eCollection 2016.
10
Label-free mass spectrometric analysis reveals complex changes in the brain proteome from the mdx-4cv mouse model of Duchenne muscular dystrophy.无标记质谱分析揭示了杜兴氏肌肉营养不良症mdx-4cv小鼠模型大脑蛋白质组的复杂变化。
Clin Proteomics. 2015 Nov 23;12:27. doi: 10.1186/s12014-015-9099-0. eCollection 2015.